Alkermes Gives Teva A Royalty-Free Path To LYBALVI Generics Starting In 2039

Pediatric exclusivity would move licensed entry to 2040, while the settlement permits an earlier launch under certain circumstances.

Share
Alkermes Gives Teva A Royalty-Free Path To LYBALVI Generics Starting In 2039

Alkermes, which develops and sells medicines for brain and nervous-system diseases, settled its LYBALVI patent case Friday, giving Teva a royalty-free license for U.S. generic entry starting November 12, 2039. The company described the agreement in an SEC filing Thursday; earlier entry is possible under certain circumstances.

The 2039 Date Has Exceptions

Teva, the applicant seeking to market a generic version of LYBALVI, would have its licensed entry moved to May 12, 2040 if Alkermes obtains pediatric exclusivity — an additional period of protection associated with pediatric drug studies. The settlement applies across all LYBALVI dosage strengths.

Alkermes will grant a limited license allowing Teva to manufacture the products covered by its generic-drug application, arrange for their manufacture, and import, use and sell them in the United States. Teva cannot transfer the license or grant sublicenses, and the license is nonexclusive, so it does not give Teva sole rights.

The dispute centered on LYBALVI patents listed in the federal Orange Book, the drug-patent reference used for generic applications. Alkermes brought the infringement lawsuit in the U.S. District Court for the District of New Jersey over Teva's application.

The companies jointly asked Monday to dismiss the pending proceedings with prejudice, meaning the same claims cannot be brought again.

LYBALVI In Alkermes' Medicine Portfolio

LYBALVI combines olanzapine and samidorphan and is among the medicines Alkermes markets in the United States for schizophrenia and bipolar I disorder. Its portfolio also includes ARISTADA and ARISTADA INITIO, VIVITROL for alcohol and opioid dependence, and LUMRYZ for narcolepsy.

Alkermes makes most of these products at its own Wilmington, Ohio, plant. It also collects royalties and manufacturing fees from partners, chiefly Janssen and Biogen, each of which accounted for about 9% of revenue in 2025.

The settlement establishes the licensing terms for a generic competitor to one of Alkermes' marketed medicines. The agreement remains subject to review by the Federal Trade Commission and the Justice Department.

Alkermes intends to include the full settlement in its annual report for the year ending December 31, 2026.

Sources

More on Alkermes

All Alkermes (ALKS) coverage →